If you are not a registered member of our community, please click here to register...


 Home Message Boards Health Guide Join for Free Testimonials About Us
Search
   
  


PDA

View Full Version : Vitamins with medications


Micro
03-26-2002, 04:25 PM
Does anyone know if it is dangerous to take vitamins with medications? I currently take Effexor, Buspar, and Trazadone. The vitamins I take are B-100, B-12, B-6, E, and C. Any responses would be appreciated. Also, taking these meds with Aspirin (Bayer).

Micro

Jay Tor
03-26-2002, 06:05 PM
Just checked for drug/drug interactions for ASA, Effexor, BuSpar and Tradozone Hydrochloride.

Here's a cut & paste of what I found - basically, the patient must be monitored very closely, as there are several major drug interactions.

From my understanding of the B vitamins, all of them affect the nervous system. That's quite a brew!

Unfortunately posting guidelines do not allow me to give you a link to the site I use for drug interactions. However, you could try a search just by typing in the key word [drugs] along with the standard internet ending [.com]. Once you do locate a drug site, check how it's operated and how often it's updated. The best ones also have additional links to research studies, scientific journals.

Good luck,
Jay

buspirone and trazodone (major Drug-Drug)
Description:
MONITOR CLOSELY: The combining of agents that can inhibit serotonin reuptake and/or other agents with serotonergic activity (including some medications for migraine therapy and certain opioids) may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5HT1A receptors. MANAGEMENT: In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Close monitoring is recommended for signs and symptoms of excessive serotonergic activity such as CNS irritability, altered consciousness, confusion, myoclonus, ataxia, abdominal cramping, hyperpyrexia, shivering, pupillary dilation, diaphoresis, hypertension, and tachycardia. Particular caution is advised when increasing the dosages of these agents.


--------------------------------------------------------------------------------
buspirone and venlafaxine (major Drug-Drug)
Description:
MONITOR CLOSELY: The combining of agents that can inhibit serotonin reuptake and/or other agents with serotonergic activity (including some medications for migraine therapy and certain opioids) may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5HT1A receptors. MANAGEMENT: In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Close monitoring is recommended for signs and symptoms of excessive serotonergic activity such as CNS irritability, altered consciousness, confusion, myoclonus, ataxia, abdominal cramping, hyperpyrexia, shivering, pupillary dilation, diaphoresis, hypertension, and tachycardia. Particular caution is advised when increasing the dosages of these agents.


--------------------------------------------------------------------------------
trazodone and venlafaxine (major Drug-Drug)
Description:
MONITOR CLOSELY: The combining of agents that can inhibit serotonin reuptake and/or other agents with serotonergic activity (including some medications for migraine therapy and certain opioids) may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5HT1A receptors. MANAGEMENT: In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk. Close monitoring is recommended for signs and symptoms of excessive serotonergic activity such as CNS irritability, altered consciousness, confusion, myoclonus, ataxia, abdominal cramping, hyperpyrexia, shivering, pupillary dilation, diaphoresis, hypertension, and tachycardia. Particular caution is advised when increasing the dosages of these agents.


--------------------------------------------------------------------------------
buspirone (moderate Drug-Food)
Description:
In a small, randomized, crossover study, the consumption of grapefruit juice (compared to water) was associated with significantly increased plasma buspirone concentrations, slightly prolonged elimination half-lives, and delayed times to reach peak drug concentration. The perceived pharmacodynamic effect of buspirone, as measured by subjective drowsiness and overall subjective drug effect, was also enhanced by grapefruit juice. These alterations may stem from the delay of gastric emptying as well as inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall induced by certain compounds present in grapefruits. Patients receiving buspirone therapy should preferably avoid the consumption of grapefruits and grapefruit juice to prevent any undue fluctuations in plasma drug levels.


--------------------------------------------------------------------------------
venlafaxine (moderate Drug-Food)
Description:
GENERALLY AVOID: Grapefruit juice has been shown to increase the plasma concentrations of some orally administered drugs, including carbamazepine, cyclosporine, dihydropyridine calcium channel blockers, lovastatin, simvastatin, midazolam and terfenadine, all of which are known substrates of the CYP450 3A4 enzymatic pathway. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits. It is not known if, and to what extent, such an interaction may occur with other substrates of CYP450 3A4. Moreover, pharmacokinetic alterations associated with interactions involving grapefruit juice are often subject to a high degree of interpatient variability. MANAGEMENT: As a precaution, it may be appropriate to avoid the consumption of grapefruit and grapefruit juice during oral therapy with all drugs that are metabolized by CYP450 3A4, particularly those with a narrow therapeutic range.

 
 
 




Site owned and operated by HealthBoards.com
Copyright and Terms of Use © 1998-2008 HealthBoards.com All rights reserved.
Do not copy or redistribute in any form!